King’s College Hospital, London, United Kingdom
TAVI has become the “standard of care” for the treatment of high-risk and surgically inoperable patients with symptomatic aortic stenosis (AS). Studies are currently recruiting which will assess whether TAVI can also be safely used in the “intermediate risk” group of patients. As a now well-established therapy, recent years have seen impressive reductions in complications and consequent improvements in outcomes and survival. The efforts of both physicians/surgeons and the device industry are now directed at refinement of the technique: addressing complications to improve outcomes and striving to make the procedure easier and more predictable. The move towards conscious ...
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next articleEAPCI Focus on the EAPCI Board Elections 2016